85 related articles for article (PubMed ID: 9156666)
1. Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly.
Caracciolo F; Capochiani E; Papineschi F; Petrini M
Leuk Lymphoma; 1997 Jan; 24(3-4):355-61. PubMed ID: 9156666
[TBL] [Abstract][Full Text] [Related]
2. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
Martelli M; Guglielmi C; Coluzzi S; Avvisati G; Amadori S; Giovannini M; Torromeo C; Mandelli F
J Clin Oncol; 1993 Dec; 11(12):2362-9. PubMed ID: 7504091
[TBL] [Abstract][Full Text] [Related]
3. Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly.
Caracciolo F; Petrini M; Capochiani E; Papineschi F; Carulli G; Grassi B
Hematol Oncol; 1994; 12(4):185-92. PubMed ID: 7528162
[TBL] [Abstract][Full Text] [Related]
4. Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphomas of the elderly.
Caracciolo F; Petrini M; Capochiani E; Papineschi F; Grassi B
Leuk Lymphoma; 1993 Sep; 11(1-2):115-8. PubMed ID: 8220144
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
[TBL] [Abstract][Full Text] [Related]
7. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
8. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
10. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
Bertini M; Freilone R; Vitolo U; Botto B; Ciotti R; Cinieri S; Di Nota A; Di Vito F; Levis A; Orsucci L; Pini M; Rota-Scalabrini D; Todeschini G; Resegotti L
Leuk Lymphoma; 1996 Aug; 22(5-6):483-93. PubMed ID: 8882962
[TBL] [Abstract][Full Text] [Related]
11. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
13. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G
Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277
[TBL] [Abstract][Full Text] [Related]
14. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
Sweetenham JW; Proctor SJ; Blaise D; De Laurenzi A; Pearce R; Taghipour G; Goldstone AH; Laurenzi A [corrected to De Laurenzi A]
Ann Oncol; 1994; 5 Suppl 2():155-9. PubMed ID: 7515646
[TBL] [Abstract][Full Text] [Related]
16. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
17. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
[TBL] [Abstract][Full Text] [Related]
18. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
19. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]